Evusheld approved in EU for COVID-19 treatment
20 September 2022 07:00 GMT Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19 Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been approved in the European Union (EU) for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID‑19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID‑19.